Compare KIO & CRMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | KIO | CRMD |
|---|---|---|
| Founded | 2011 | 2006 |
| Country | United States | United States |
| Employees | 2400 | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 469.6M | 876.7M |
| IPO Year | N/A | 2010 |
| Metric | KIO | CRMD |
|---|---|---|
| Price | $11.56 | $11.61 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $17.43 |
| AVG Volume (30 Days) | 136.5K | ★ 2.9M |
| Earning Date | 01-01-0001 | 11-12-2025 |
| Dividend Yield | ★ 10.82% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 2.25 |
| Revenue | N/A | ★ $214,303,672.00 |
| Revenue This Year | N/A | $627.89 |
| Revenue Next Year | N/A | $40.95 |
| P/E Ratio | ★ N/A | $5.10 |
| Revenue Growth | N/A | ★ 1647.67 |
| 52 Week Low | $10.52 | $5.60 |
| 52 Week High | $13.59 | $17.43 |
| Indicator | KIO | CRMD |
|---|---|---|
| Relative Strength Index (RSI) | 38.51 | 61.66 |
| Support Level | $11.67 | $10.90 |
| Resistance Level | $11.65 | $12.10 |
| Average True Range (ATR) | 0.08 | 0.50 |
| MACD | 0.02 | 0.24 |
| Stochastic Oscillator | 39.29 | 83.07 |
KKR Income Opportunities Fund operates as a closed-end registered management investment company. It seeks to generate a high level of current income, with a secondary objective of capital appreciation. The company invests in the portfolio of loans and fixed-income instruments of U.S. and non-U.S. issuers. The company will invest at least 80% of its Managed Assets in loans and fixed-income instruments or other instruments, including derivative instruments, with similar economic characteristics under normal market conditions.
Cormedix Inc is a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions. The Company's focus is on the commercialization of its product, DefenCath, in the United States (U.S.) and other key markets. The group currently operates in a single segment, Drug Product, located in a single geographic location, the United States.